Skip to main content
. 2021 Jul 21;61(4):1717–1727. doi: 10.1093/rheumatology/keab580

Fig. 2.


Fig. 2

Effects of bleomycin treatment and ALK5 inhibition on markers of collagen formation and lung function

(A) Hydroxyproline content of skin tissue. (B) Hydroxyproline content of lung tissue (ml: middle lobe; il: inferior lobe; pcl: postcaval lobe). (C) Lung function as assessed by flexiVent analysis. (BLM: bleomycin; ALK5i: the ALK5 inhibitor SB525334). Error bars represent SEM. Statistical significance was assessed using one-way ANOVA with Bonferroni’s correction.